Healthy Returns: New weight loss drug data show Eli Lilly is gaining ground
1. Eli Lilly's orforglipron showed effective weight loss in late-stage trials. 2. Bimagrumab may enhance fat loss while preserving muscle mass in users. 3. Novo Nordisk faces challenges with its CagriSema weight loss drug results. 4. Analysts expect positive outcomes from Eli Lilly’s upcoming obesity drug portfolio. 5. Weight loss drug market could exceed $150 billion by decade's end.